Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease

Haematologica

Volumn 97, Issue 5, 2012, Pages 717-722

  Gutiérrez Aguirre, Cesar Homero ^a   Cantú Rodríguez, Olga Graciela ^a   Borjas Almaguer, Omar David ^a   González Llano, Oscar ^a   Jaime Pérez, José Carlos ^a   Solano Genesta, Manuel ^a   Gómez Guijosa, Miguel ^a   Mancias Guerra, Consuelo ^a   Tarin, Luz ^a   Gómez Almaguer, David ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Alemtuzumab; Graft versus host disease; Hematopoietic stem cell transplant; Rituximab

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CHLORPHENIRAMINE; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; HYDROCORTISONE; PARACETAMOL; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; BRONCHITIS; CHILL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ENTEROPATHY; EYE DISEASE; FEMALE; FEVER; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; INFECTION; LARYNGITIS; LIVER DISEASE; LOW DRUG DOSE; LUNG DISEASE; MALE; MULTIPLE CYCLE TREATMENT; ORAL MUCOSAL DISEASE; OVERALL SURVIVAL; PHOTOTHERAPY; PNEUMONIA; PROSPECTIVE STUDY; RASH; RELAPSE; REMISSION; REPEATED DRUG DOSE; RHODOCOCCUS EQUI; SINUSITIS; SKIN DISEASE; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; STEROIDS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84860550711     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.054577     Document Type: Article

References (35)

1. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28(3):250-9.
2. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-56.
3. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood. 2005;105(11):4200-6.
4. Bolanos-Meade J, Vogelsang GB. Chronic graft-versus-host disease. Curr Pharm Des. 2008;14(20):1974-86.
5. Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2011;17(1):1-17.
6. Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler E. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des. 2009;15(17):1974-97.
7. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005; 31(6):456-73.
8. Kharfan-Dabaja MA, Bazarbachi A. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16 (10):1347-54.
9. Ho VT, Cutler C. Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol. 2008;21(2):223-37.
10. Christian BA, Lin TS. Antibody therapy for chronic lymphocytic leukemia. Semin Hematol. 2008;45(2):95-103.
11. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al. In vivo CAMPATH-1H prevents graftversus- host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96(7):2419-25.
12. Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood. 2010;116(16):3080-8.
13. Gomez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-Arzaga L, Gonzalez-Llano O, Gutierrez-Aguirre H, Cantu-Rodriguez O, et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(1):10-5.
14. Ruiz-Arguelles GJ, Gil-Beristain J, Magana M, Ruiz-Delgado GJ. Alemtuzumabinduced resolution of refractory cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(1):7-9.
15. Schub N, Gunther A, Schrauder A, Claviez A, Ehlert C, Gramatzki M, et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant. 2011;46(1):143-7.
16. Martinez C, Solano C, Ferra C, Sampol A, Valcarcel D, Perez-Simon JA. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. Biol Blood Marrow Transplant. 2009;15(5):639-42.
17. Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K, Hidaka M, et al. Rituximab for the treatment of corticosteroid- refractory chronic graft-versus-host disease. Int J Hematol. 2009;90(2):253-60.
18. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy- refractory chronic graft-versus-host disease. Blood. 2004;104(8):2603-6.
19. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-62.
20. Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006;20(1):172-3.
21. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40(3):273-7.
22. Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant. 2008;41(10):909-11.
23. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and metaanalysis. Biol Blood Marrow Transplant. 2009;15(9):1005-13.
24. Dierickx D, Delannoy A, Saja K, Verhoef G, Provan D. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Am J Hematol. 2011;86 (3):278-91.
25. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007;92(12):1695-8.
26. Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93(6):930-3.
27. Nabhan C, Patton D, Gordon LI, Riley MB, Kuzel T, Tallman MS, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004;45(11):2269-73.
28. Gomez-Almaguer D, Solano-Genesta M, Tarin-Arzaga L, Herrera-Garza JL, Cantu- Rodriguez OG, Gutierrez-Aguirre CH, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783-5.
29. Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol. 2006;176(10):6147-54.
30. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15(1):e2-16.
31. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximabrelated viral infections in lymphoma patients. Leuk Lymphoma. 2007;48(7):1307-12.
32. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 2007;123(1):66-73.
33. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52(2):501-13.
34. Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim SH, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis. 2009;11(5):413-23.
35. Drancourt M, Bonnet E, Gallais H, Peloux Y, Raoult D. Rhodococcus equi infection in patients with AIDS. J Infect. 1992;24(2):123-31.